Literature DB >> 16314697

Magnetic resonance imaging and expression of vascular endothelial growth factor in hepatocellular nodules in cirrhosis and hepatocellular carcinomas.

Masayuki Kanematsu1, Richard C Semelka, Shinji Osada, Nozomi Amaoka.   

Abstract

We summarized and discussed our previous research results on correlation between magnetic resonance (MR) imaging findings and vascular endothelial growth factor (VEGF) expression in benign or borderline hepatocellular nodules in cirrhosis, hepatocellular carcinomas (HCCs), and in the surrounding liver. Magnetic resonance images were retrospectively correlated quantitatively and qualitatively with VEGF expression in hepatic nodules and in the surrounding liver. By immunohistochemistry, hepatic nodules with moderate to strong immunoreactivity for VEGF showed higher T1 signal intensity, and those with intense immunoreactivity for VEGF showed higher T2 signal intensity. By Western blotting, HCC-to-liver contrast-to-noise ratio correlated with VEGF indices (VEGFs) of hepatocellular carcinomas inversely on opposed-phase T1-weighted, directly on T2-weighted, and marginally and inversely on gadolinium-enhanced hepatic arterial-phase images. On T2-weighted images, standard-deviation ratio of hepatocellular carcinomas correlated directly with VEGFs of hepatocellular carcinomas. Heterogeneities of hepatocellular carcinomas on MR images correlated directly with VEGFs of HCCs on opposed-phase T1-weighted, T2-weighted, hepatic arterial-phase, and equilibrium-phase images. Our results may reflect that MR signal intensity, hepatic arterial vascularity, and heterogeneity of hepatocellular nodules on MR images are closely related to the intensity of VEGF expression as up-regulated by hyper- or hypoxia in the nodules. Gadolinium-enhanced MR imaging may be useful to monitor ischemic state of hepatocelluar nodules. Although real impacts of our results on radiologic practice have been still debatable, we believe that our results may help future radiologic practice in conjunction with biomolecular or genetic treatments for hepatocellular carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314697     DOI: 10.1097/01.rmr.0000191133.91603.d2

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  5 in total

Review 1.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

2.  Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.

Authors:  Xuan Wang; Jieyu Ding; Yuanyuan Feng; Lingling Weng; Guangqiang Zhao; Jianfeng Xiang; Minguang Zhang; Dongwei Xing
Journal:  Oncol Lett       Date:  2017-01-17       Impact factor: 2.967

Review 3.  Molecular targeted therapy for hepatocellular carcinoma.

Authors:  Melanie Thomas
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

4.  Expression characteristics of KAI1 and vascular endothelial growth factor and their diagnostic value for hepatocellular carcinoma.

Authors:  Wu Zhang; Cheng Guang Zhao; Hong Yu Sun; Wei E Zheng; Hua Chen
Journal:  Gut Liver       Date:  2014-07-25       Impact factor: 4.519

5.  miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4.

Authors:  Liangtian Shao; Qing Ye; Moyang Jia
Journal:  J Healthc Eng       Date:  2021-07-23       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.